merged_alzheimers-treatment-kisunla-donanemab.txt
<other>First, I will identify the relevant sections of the article that address each question. For each question, I will extract the specific information required to form a direct answer.</other>
<question_number>1</question_number>
<answer>Significant safety risks, including swelling and bleeding in the brain.</answer>
<question_number>2</question_number>
<answer>It might discourage patients from participating in trials for treatments that could be better.</answer>
<question_number>3</question_number>
<answer>There's no correlation between the removal of amyloid plaques and the clinical response in individual subjects.</answer>
<question_number>4</question_number>
<answer>It could lead to a perception that Kisunla is less safe.</answer>
<question_number>5</question_number>
<answer>The higher price reflects the expectation that patients can stop Kisunla after their plaques are cleared.</answer>
<question_number>6</question_number>
<answer>It might discourage patients from participating in other clinical trials.</answer>
<question_number>7</question_number>
<answer>Patients can stop the drug after it clears the protein, amyloid, reducing overall cost, inconvenience, and risk of side effects.</answer>
<question_number>8</question_number>
<answer>Amyloid.</answer>
<question_number>9</question_number>
<answer>Dr. Michael Greicius.</answer>
<question_number>10</question_number>
<answer>Trial participants with intermediate tau levels declined more slowly on donanemab than those with high levels.</answer>